Woburn, Massachusetts, May 1, 2026, 14:02 EDT
- ISPC shares whipsawed Friday, coming off iSpecimen’s first full week post 1-for-40 reverse split.
- This matters: the split was designed to help the company satisfy Nasdaq’s minimum bid-price requirement.
- Cash burn is under scrutiny, along with a going-concern warning and the annual meeting, now pushed to May 8.
iSpecimen Inc. shares slid to $4.80 by 14:01 Friday, down 8.2% for the day, according to Investing.com. Earlier in the session, the price swung from $4.795 to $6.77. Thursday saw a 22.5% jump, capping off a turbulent week since the company’s 1-for-40 reverse split kicked in.
The real issue here is the split, which goes beyond appearances—it’s about staying on the Nasdaq. iSpecimen announced its reverse split took effect at 4:30 p.m. Eastern on April 27. ISPC shares started trading split-adjusted on April 28. The move, according to the company, aims to boost the share price and meet Nasdaq Capital Market listing requirements.
The clock is ticking. In a November filing, Nasdaq notified iSpecimen that its shares had spent 30 straight business days under the $1 minimum bid, triggering a deadline: the company has until May 18, 2026, to fix the issue. To regain compliance, iSpecimen needs a closing bid of at least $1 for a minimum of 10 consecutive business days.
A reverse split won’t fix cash flow problems or boost demand on its own—it simply consolidates shares. iSpecimen rolled 40 shares into one, reducing its issued and outstanding shares sharply, from roughly 52.6 million down to 1.3 million. Any leftover fractions were bumped up to the next whole share.
With only about 1.32 million shares outstanding, iSpecimen’s trading can appear exaggerated. Google Finance pegged its market cap at roughly $6.66 million Friday afternoon, keeping ISPC deep in microcap territory—where small trades can hit the price hard.
Governance questions still linger. In April, a filing revealed iSpecimen’s 2025 annual meeting couldn’t get off the ground after multiple adjournments due to a lack of quorum. The company now intends to give it another shot on May 8 at 9:00 a.m. Eastern, keeping the slate of proposals unchanged.
iSpecimen is a niche operation. The company operates an online marketplace connecting medical researchers with providers of human biospecimens—blood, tissue, cells, and more. Its network brings together hospitals, labs, biobanks, and other suppliers.
Management has been steering investors to focus on operational improvements. Back on April 9, the company highlighted its shift to a direct-to-customer shipping model, claiming it slashed transit times roughly 70% to 85%. Domestic orders can now arrive within one to two days. Chief Executive Katie Field called the update evidence of “operational flexibility and expertise.”
The field isn’t bare. iSpecimen’s annual filing names Discovery Life Sciences and StemExpress as specimen suppliers running in-house biobanks, while Science Exchange shows up as a research-services marketplace. According to the company, its toughest competition comes from bigger, better-capitalized providers with wide-ranging sample access and deeper inventories.
But the split leaves the central risk squarely in place. iSpecimen posted 2025 revenue of $1.93 million, a sharp drop from $9.29 million in 2024. Net loss? Only a modest improvement—$10.49 million versus $12.50 million the prior year. The company’s annual filing flagged “substantial doubt” about its ability to stay afloat—audit-speak for possible funding needs or the pressure to improve performance. SEC
Year-end cash finished higher, though the cushion remained thin relative to the loss. As of Dec. 31, 2025, the company reported $6.88 million in cash and cash equivalents. Operating activities burned through $4.24 million that year, but $10.24 million was raised from financing.
ISPC isn’t moving like your standard life-sciences growth play at the moment. Right now, it’s behaving more like a thinly traded microcap squeezed between a Nasdaq compliance deadline and management’s turnaround efforts. Investors are watching three things: the closing price, the outcome of the annual meeting, and any signs that quicker shipping or marketplace tweaks actually lift revenue.
